HEALTH TECHNOLOGY

HealthVerity Launches Cloud Platform Offering Flexible Technologies Empowering Healthcare Enterprises

HealthVerity | November 17, 2020

HealthVerity, the pioneer in security ensured data exchange, today reported the business accessibility of its incorporated cloud stage offering adaptable advancements that enable medical care endeavors to plan and assemble their own one of a kind data technique, data work process or data universe, all in a security ensured way. Upheld by an amazing API (application programming interface) suite, HealthVerity customers can rapidly coordinate these advancements straightforwardly into their current data and examination work processes to convey development in new and novel manners.

The new HealthVerity stage presents a structure based on the primary components of Activate, Discover, Exchange, Govern, Organize and Deliver, urging customers to consolidate either select abilities or the full suite to all the more likely favorable position their most significant undertaking data work processes. Presently accessible for sure fire engineer use are more than two dozen APIs pre-worked to empower capacities, for example, security ensured character goal, venture wide assent the executives, multi-party data exchange and by and large data administration, among others. As a component of the dispatch, HealthVerity has advanced HealthVerity Marketplace, the cloud answer for finding and authorizing the country's biggest medical services data biological system, to incorporate direct admittance to its new API layer.

"Over 250 leading life sciences and insurance enterprises trust us to safeguard privacy, drive data interoperability and enrich their data-driven applications," said Andrew Kress, CEO of HealthVerity. "Whether it's linking and managing the combination of specialty drug data with deidentified healthcare data for new patients, boosting signal for clinical trial cohorts in real-time or consolidating disparate datasets, all in a HIPAA-compliant manner, our clients can more rapidly and efficiently enable these outcomes via a self-service API suite.

Over the coming months, HealthVerity will continue to announce new additions to its platform to support a wide range of data management requirements and to ensure that all clients are able to reimagine and benefit from the modern way to data.

About HealthVerity

For transformative, evidence-led healthcare companies, HealthVerity enables the creation and execution of unique end-to-end data strategies with privacy and HIPAA-compliance at the forefront.  With HealthVerity technologies directly embedded into the enterprise workflow and the largest, most flexible data ecosystem at their fingertips, our partners benefit from cloud solutions spanning expert patient identity resolution to secure data management and transformation.  From activation to delivery, HealthVerity is the modern way to data.

Spotlight

The Patient Protection & Affordable Care Act (PPACA), commonly referred to as The Affordable Care Act and otherwise known as "Obamacare", was signed into law in 2010 and became effective January 1, 2014. As a result, the United States can expect to see an accelerated demand for an increased investment in the commercial real estate, especially medical office buildings. What winning strategies are investors adopting in response to healthcare reform?


Other News
FUTURE OF HEALTHCARE

Virta Health Highlights Lasting, Transformative Health Improvements In 5-Year Diabetes Reversal Study

Virta Health | June 07, 2022

Virta Health, the leader in type 2 diabetes reversal, revealed preliminary five-year results from its landmark clinical trial at the American Diabetes Association 82nd Scientific Sessions. Presenting four unique abstracts, Virta highlighted myriad, lasting health improvements for people with type 2 diabetes and prediabetes, including blood sugar control, clinically-significant weight loss, reduced inflammation, and improvements in other markers of cardiometabolic health. These transformative health outcomes coincided with medication reduction or elimination for many trial patients, including Jane Ann Dimitt. For over two decades, Jane Ann was prescribed increasing levels of medications as her blood sugar and weight continued to climb. By the time she joined Virta in 2015, her A1c had reached 11.4%; the next step was insulin. Through Virta’s treatment, Jane Ann lowered her blood sugar to 5.5% (below even the prediabetes threshold) and lost over 50 pounds, while drastically reducing her reliance on medications. She also saw improved mobility, decreased inflammation and neuropathy, and now has the energy to play with her grandchildren—all without needing the insulin doctors said was imminent. The outcomes of Jane Ann and Virta’s other trial patients contradict the belief that progression of diabetes—and a lifetime of increasing medications—is inevitable. One-fifth of Virta patients completing five years of treatment saw full remission. One-third of patients achieved A1c below 6.5% without any diabetes medications, or only requiring Metformin. Notably, inflammatory markers, triglycerides, and HDL cholesterol all improved significantly. These outcomes, in conjunction with previous research demonstrating improvements in cardiovascular disease risk factors, depression symptoms, sleep, and knee pain, establish the promise of Virta’s approach to impact a wide range of conditions amid America’s metabolic disease epidemic. In the U.S., costs are rising as patient outcomes continue to worsen, including surges in amputations, hyperglycemic events, and diabetes-related deaths during the COVID-19 pandemic. Meanwhile, getting patients to stick with an intervention remains a significant challenge in diabetes therapy. Rates of medication adherence—that is, whether patients take their medications as prescribed—fall as low as 34% over the first three years for those starting insulin. For the National Diabetes Prevention Program, considered the gold standard in lifestyle interventions, only 13% of patients were retained at one year. In contrast, in Virta’s trial nearly 50% of participants with type 2 diabetes were retained at five years. Of those who continued past year two, 72% remained for an additional three years to year five. For Kim Shepherd, who lost 55 pounds, eliminated 10 different medications, reversed her diabetes, and even saw her GERD (acid reflux) and plantar fasciitis disappear, the reasons to stick with the treatment are clear. “Diabetes runs in my family, and I know that this disease can rob you of your whole life; it can take your eyes, your feet, and your kidneys. I have 4 kids and 9 grandkids to keep up with. I’ve learned to love hiking and biking. Nothing is worth losing all of that and going back to how I was before.” Additional key outcomes demonstrating the success of Virta’s approach at five years include Sustained blood sugar control. Virta patients experienced persistent improvements in blood sugar on average, while requiring significantly fewer medications. Medication deprescription. Half of patients prescribed insulin at the start of the trial no longer needed it at five years. Across all diabetes drugs, prescriptions were reduced by nearly 50%. Weight loss. Average weight among Virta participants decreased by 7.6%, exceeding the 5% benchmark for clinically significant weight loss by more than 50%. Broad improvement in cardiometabolic health. In addition to improvements in triglycerides, HDL cholesterol, and markers of inflammation, patients even showed encouraging signs in reversing the progression of chronic kidney disease. “Virta’s patients are helping redefine what long-term success can look like in type 2 diabetes care. The patient outcomes set a new standard for real-world applications of diabetes treatment." Dr. Alan Moses, former Senior Vice President and Global Chief Medical Officer of Novo Nordisk, and Virta advisor Trial participants with prediabetes also saw meaningful improvements, with progression rates far below what has been demonstrated in other studies. Further, Virta patients sustained 6% weight loss over five years, exceeding the clinically-significant benchmark for diabetes prevention and far surpassing the 2% weight loss observed in the NIH Diabetes Prevention Program lifestyle intervention. The study is also notable for its longevity. Five-year published results are extremely rare in digital health, where most studies follow populations for no more than a year, and usually significantly less. For many Virta patients, the five-year clinical trial has facilitated a lasting lifestyle change, improving not only traditional markers of health but overall mood, quality of life, and outlook on the future. Says patient Denise Lamb, who has maintained diabetes reversal alongside a nearly 70 pound weight loss, “My journey has been phenomenal. The Virta program has not only helped me achieve healthy blood glucose, but also attain a far better weight, normal blood pressure, and better understanding of my body. Virta’s lifestyle changed my lifestyle!” About Virta Health Virta Health helps people reverse type 2 diabetes and other chronic conditions. Current approaches manage disease progression through increased medication use and infrequent doctor visits. Virta reverses type 2 diabetes through innovations in technology, nutrition science, and continuous remote care from physicians and behavioral experts. In clinical studies, 94% of patients reduce or eliminate insulin use, and weight-loss exceeds FDA benchmarks by nearly 150%. Virta works with the largest health plans, employers, and government organizations and puts 100% of its fees at risk based on clinical and financial outcomes.

Read More

HEALTH TECHNOLOGY

NUTEX HEALTH ANNOUNCES TWO NEW FULLY FUNCTIONAL MICRO HOSPITALS

Nutex Health, Inc. | May 17, 2022

Nutex Health Inc. a physician-led, technology-enabled healthcare services company comprised of a hospital division with 21 facilities in 8 states and a primary care-centric, risk-bearing population health management division, announced two new fully operational micro hospitals. The first hospital, New Braunfels ER & Hospital, is in New Braunfels, Texas, located about 30 miles northeast of San Antonio. The state-of-the-art facility is open 24/7, 365 days a year, and includes an emergency room with 9 private exam rooms staffed with board-certified physicians and 4 private inpatient beds. The hospital provides both adult and pediatric care, and has the most advanced imaging and laboratory equipment, including CT, X-Ray and ultrasound with rapid radiological reports. The second hospital, East Valley ER & Hospital, is in Gilbert, Arizona, located about 21 miles southeast of Phoenix. The state-of-the-art hospital is open 24/7, 365 days a year, and includes an emergency room with 14 private exam rooms and 14 private inpatient beds. The hospital provides both adult and pediatric care, and has the most advanced imaging and laboratory equipment, including MRI, CT, X-Ray and ultrasound. Nutex currently anticipates opening 3 more facilities in 2022, with another 17 facilities either under construction or in advanced planning stages and anticipated to open in 2023 and 2024. There can be no assurance that these additional facilities will open in the anticipated timing or that they will open at all. Nutex micro hospitals focus on ensuring that patients receive a premium patient experience. Our hospitals feature short ER wait times averaging 15 minutes from entering the door to seeing a physician, high-quality care, lower nursing- and physician-to-patient staffing ratios and faster discharge times. Physicians, nurses and other employees are incentivized to provide quality, compassionate care to their patients. Nutex micro hospitals consistently have better outcomes and high patient satisfaction scores, with well over 1000 five-star Google reviews. "We are excited to continue to expand Nutex's network of micro hospitals across the country. Both New Braunfels and Gilbert are vibrant and rapidly growing suburbs of major metropolitan areas. Our goal is to provide high-quality acute medical care to the populations of these communities." Tom Vo, M.D., MBA, Chairman and Chief Executive Officer of Nutex Health "Entering the medical field, my goal was always to try to revolutionize the way healthcare is delivered to our patients. Our unique model allows physicians and nurses to retake control of patient care," stated Trey Allen, M.D., Medical Director at New Braunfels ER & Hospital. "We are committed to working with the community to make sure they can receive the healthcare they deserve." "As physicians, we saw how healthcare was being delivered, and we felt we could do better. We felt the humanity and compassion were absent from many medical interactions. We value and respect our patients, and treat them as family," stated Daniel Stites, M.D., Medical Director at East Valley ER & Hospital. About Nutex Health Inc. Headquartered in Houston, Texas and founded in 2011, Nutex Health Inc. is a physician-led, technology-enabled healthcare services company with approximately 1500 employees nationwide and is partnered with over 800 physicians. The Company has two divisions a Hospital division and a Population Health Management division. The hospital division owns and operates 21 facilities in eight different states. The division implements and operates different innovative health care models, including micro hospitals, specialty hospitals and hospital outpatient departments. The Population Health Management division owns and operates provider networks such as Independent Physician Associations (IPAs). Through our Management Services Organizations, we provide management, administrative and other support services to our affiliated hospitals and physician groups. Our cloud-based proprietary technology platform aggregates clinical and claims data across multiple settings, information systems and sources to create a holistic view of patients and providers, allowing us to deliver greater quality care more efficiently. Safe Harbor Certain statements and information included in this press release constitute "forward-looking statements" within the meaning of the Federal Private Securities Litigation Act of 1995. When used in this press release, the words or phrases "will", "will likely result," "expected to," "will continue," "anticipated," "estimate," "projected," "intend," "goal," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include the ability to realize the anticipated benefits of the transaction, significant transaction costs and unknown liabilities and litigation and regulatory risks related to the transaction. In addition, forward-looking statements are subject to additional uncertainties and risks facing the Company, including but not limited to, economic conditions, dependence on management, dilution to stockholders, lack of capital, changes in laws or regulations, the effects of rapid growth upon the Company and the ability of management to effectively respond to the growth and demand for products and services of the Company, newly developing technologies, the Company's ability to compete, conflicts of interest in related party transactions, regulatory matters, protection of technology, lack of industry standards, the effects of competition and the ability of the Company to obtain future financing. Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed within this press release.

Read More

HEALTH TECHNOLOGY

Bright Health Group Expands Executive Team as It Drives Performance in Scaled Businesses

Bright Health Group | May 18, 2022

Bright Health Group, Inc. the first technology-enabled, Fully Aligned System of Care built for healthcare's consumer retail market,announced the expansion of its leadership team with the addition of Michael Carson as Bright HealthCare Chief Executive Officer and Jeff Cook as NeueHealth Chief Executive Officer. These proven leaders, reporting directly to Bright Health Group CEO Mike Mikan, will focus on leading the Company’s two complementary businesses, as Bright HealthCare has gained scale, and NeueHealth emerges as a differentiated market player. Carson will lead the Bright HealthCare business, which has reached scale, and will focus on driving core operational excellence, innovative consumer product and network solutions and profitable, sustainable growth. Carson brings deep experience across the payer and provider space, along with a passion for integrated and transformative healthcare innovation that drives better healthcare outcomes, experiences, and value. Most recently, Carson served as Chief Executive Officer of CareAbout, a multi-market, value-based primary and multi-specialty care start-up, and as President and Chief Executive Officer of Harvard Pilgrim Health Care, a leading not-for-profit health services company. Previously, Carson held leadership positions at Anthem, AmeriGroup, Blue Cross Blue Shield plans, and ConcertoHealth. Cook will lead NeueHealth, Bright Health Group’s personalized care delivery business, which has emerged as a differentiated market player. He will continue to grow and develop our Integrated Systems of Care. Throughout his career, Cook has consistently led initiatives that are at the forefront of value-based care and consumer-driven healthcare. Previously, Cook served as national Vice President of CVS Health HUBs, CVS’ suite of HUB clinical services. Prior to that, Cook served as the South Central Regional President of CVS Health/Aetna and held various leadership positions at Ascension Health and UnitedHealthcare. “Michael and Jeff both bring strong expertise in their respective domains, and most importantly, have a passion for and expertise in fully aligned, value-based care. As we embark on this next phase of Bright Health Group’s journey, we are excited to have these two phenomenal leaders join our already deep bench of talent within Bright HealthCare and NeueHealth.” Mike Mikan, President and CEO, Bright Health Group Sam Srivastava, current CEO of NeueHealth, will serve as a strategic advisor through the end of May to ensure a smooth transition. Jay Matushak, current Interim CEO of Bright HealthCare, will be returning to his previous role as CFO of Bright HealthCare, while taking on an expanded set of responsibilities. Said Mikan, “We want to thank Sam for his many contributions to Bright Health Group and Jay for stepping up to lead Bright HealthCare in the interim. Jay has done a terrific job progressing Bright HealthCare and we look forward to him partnering with Michael as they continue the build on our platform for change in healthcare.” About Bright Health Group Bright Health Group is the first technology-enabled, Fully Aligned System of Care built for healthcare's consumer retail market. Our differentiated approach aligns care delivery with the financing of care to drive better outcomes, lower costs, and enhance the consumer experience. We have two market-facing businesses: NeueHealth and Bright HealthCare. NeueHealth provides care delivery and value-based enablement services to over 500,000 value-based patients through our owned and affiliated clinics. Bright HealthCare offers Commercial and Medicare health plan products to over 1.1 million consumers across the nation. We believe everyone should have access to personal, affordable, and high-quality healthcare. Our mission is to Make healthcare right. Together.

Read More

FUTURE OF HEALTHCARE

Winner Medical Acquires Majority Stake in Pingan Medical to Fuel Growth

Winner Medical | June 02, 2022

Winner Medical Co. Ltd. a leading manufacturer of disposable wound care and surgical products, announced on May 18 that it will acquire a majority 65.55% stake in Hunan Pingan Medical Device Technology Co. Ltd. for 652 million yuan as the Company continues to expand its disposable medical supply lineup. Upon the completion of the deal, Winner Medical is set to hold a total of 68.7% stake in Pingan Medical for a total of 752 million yuan. The Company's move comes as it looks to make a foray into the field of injection products to diversify its product offerings besides consumer products, and comes in line with its strategy to provide one-stop disposable medical supply solutions. Established in 2010, Pingan Medical mainly produces disposable medical devices, such as syringes, infusion sets, and blood collection tubes among other medical supplies. In 2021, Pingan Medical recorded 360 million yuan in revenue and booked a net profit of 85 million yuan. The acquisition will leverage both companies' strengths and help fill the product gap in injection-related disposables of Winner Medical, enabling it to expand into new medical verticals and achieve its goal of becoming a major supplier for the domestic market. Specifically, the Company plans to roll out medical sets that comprise needle-type products from Pingan Medical and wound care supplies from Winner Medical, providing one-stop customized solutions for hospitals and large medical centers. Meanwhile, Winner Medical will help Pingan Medical with its industry-leading R&D capabilities to develop medical device solutions and build smart manufacturing plants. To fuel the growth based on the new deal, Winner Medical has signed an investment note with the local government of Li County in Hunan Province, where Pingan Medical is headquartered, to build medical equipment production lines, smart warehousing, and R&D facilities. The latest deal follows Winner Medical's April-11 acquisition of wound dressing maker Zhejiang Longterm Medical Technology Co. Ltd. as part of its expansion strategy to stay competitive in the area of high-end wound dressings. The Company has also set up a dedicated team to promote its self-developed wound dressing products as the market for such medical supplies is still in its infancy in China. Founded in 1991, Winner Medical has made efforts to offer quality cotton-based medical dressings and disposables, and will continue to push ahead with its strategy to diversify its product lineup and boost consumption. On the manufacturing front, the Company aims to expand to new medical verticals through acquisitions, while on the consumption front, it plans to enhance product sales through digitization and gradually phasing out less popular products. As such, the Company has made significant progress in digitizing its operations. Winner Medical has gone live on multiple e-commerce platforms, and has gone digital in terms of online and offline warehousing and order management.

Read More

Spotlight

The Patient Protection & Affordable Care Act (PPACA), commonly referred to as The Affordable Care Act and otherwise known as "Obamacare", was signed into law in 2010 and became effective January 1, 2014. As a result, the United States can expect to see an accelerated demand for an increased investment in the commercial real estate, especially medical office buildings. What winning strategies are investors adopting in response to healthcare reform?

Resources